Advanced search
1 file | 368.78 KB

Treatment of central sensitization in patients with 'unexplained' chronic pain: what options do we have?

(2011) EXPERT OPINION ON PHARMACOTHERAPY. 12(7). p.1087-1098
Author
Organization
Abstract
Introduction: Central sensitization accounts for chronic 'unexplained' pain in a wide variety of disorders, including chronic whiplash-associated disorders, temporomandibular disorders, chronic low back pain, osteoarthritis, fibromyalgia, chronic fatigue syndrome and chronic tension-type headache among others. Given the increasing evidence supporting the clinical significance of central sensitization in those with unexplained chronic pain, the awareness is growing that central sensitization should be a treatment target in these patients. Areas covered: This article provides an overview of the treatment options available for desensitizing the CNS in patients with chronic pain due to central sensitization. It focuses on those strategies that specifically target pathophysiological mechanisms known to be involved in central sensitization. In addition, pharmacological options, rehabilitation and neurotechnology options are discussed. Expert opinion: Acetaminophen, serotonin-reuptake inhibitor drugs, selective and balanced serototin and norepinephrine-reuptake inhibitor drugs, the serotonin precursor tryptophan, opioids, N-methyl-D-aspartate (NMDA)-receptor antagonists, calcium-channel alpha(2)delta (a2 delta delta) ligands, transcranial magnetic stimulation, transcutaneous electric nerve stimulation (TENS), manual therapy and stress management each target central pain processing mechanisms in animals that - theoretically - desensitize the CNS in humans. To provide a comprehensive treatment for 'unexplained' chronic pain disorders characterized by central sensitization, it is advocated to combine the best evidence available with treatment modalities known to target central sensitization.
Keywords
therapy, physical therapy, central sensitization, chronic pain, medication

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 368.78 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Nijs, Jo, Mira Meeus, Jessica Van Oosterwijck, Nathalie Roussel, Margot De Kooning, Kelly Ickmans, and Milica Matic. 2011. “Treatment of Central Sensitization in Patients with ‘Unexplained’ Chronic Pain: What Options Do We Have?” Expert Opinion on Pharmacotherapy 12 (7): 1087–1098.
APA
Nijs, Jo, Meeus, M., Van Oosterwijck, J., Roussel, N., De Kooning, M., Ickmans, K., & Matic, M. (2011). Treatment of central sensitization in patients with “unexplained” chronic pain: what options do we have? EXPERT OPINION ON PHARMACOTHERAPY, 12(7), 1087–1098.
Vancouver
1.
Nijs J, Meeus M, Van Oosterwijck J, Roussel N, De Kooning M, Ickmans K, et al. Treatment of central sensitization in patients with “unexplained” chronic pain: what options do we have? EXPERT OPINION ON PHARMACOTHERAPY. 2011;12(7):1087–98.
MLA
Nijs, Jo, Mira Meeus, Jessica Van Oosterwijck, et al. “Treatment of Central Sensitization in Patients with ‘Unexplained’ Chronic Pain: What Options Do We Have?” EXPERT OPINION ON PHARMACOTHERAPY 12.7 (2011): 1087–1098. Print.
@article{2014551,
  abstract     = {Introduction: Central sensitization accounts for chronic 'unexplained' pain in a wide variety of disorders, including chronic whiplash-associated disorders, temporomandibular disorders, chronic low back pain, osteoarthritis, fibromyalgia, chronic fatigue syndrome and chronic tension-type headache among others. Given the increasing evidence supporting the clinical significance of central sensitization in those with unexplained chronic pain, the awareness is growing that central sensitization should be a treatment target in these patients. 
Areas covered: This article provides an overview of the treatment options available for desensitizing the CNS in patients with chronic pain due to central sensitization. It focuses on those strategies that specifically target pathophysiological mechanisms known to be involved in central sensitization. In addition, pharmacological options, rehabilitation and neurotechnology options are discussed. 
Expert opinion: Acetaminophen, serotonin-reuptake inhibitor drugs, selective and balanced serototin and norepinephrine-reuptake inhibitor drugs, the serotonin precursor tryptophan, opioids, N-methyl-D-aspartate (NMDA)-receptor antagonists, calcium-channel alpha(2)delta (a2 delta delta) ligands, transcranial magnetic stimulation, transcutaneous electric nerve stimulation (TENS), manual therapy and stress management each target central pain processing mechanisms in animals that - theoretically - desensitize the CNS in humans. To provide a comprehensive treatment for 'unexplained' chronic pain disorders characterized by central sensitization, it is advocated to combine the best evidence available with treatment modalities known to target central sensitization.},
  author       = {Nijs, Jo and Meeus, Mira and Van Oosterwijck, Jessica and Roussel, Nathalie and De Kooning, Margot and Ickmans, Kelly and Matic, Milica},
  issn         = {1465-6566},
  journal      = {EXPERT OPINION ON PHARMACOTHERAPY},
  keyword      = {therapy,physical therapy,central sensitization,chronic pain,medication},
  language     = {eng},
  number       = {7},
  pages        = {1087--1098},
  title        = {Treatment of central sensitization in patients with 'unexplained' chronic pain: what options do we have?},
  url          = {http://dx.doi.org/10.1517/14656566.2011.547475},
  volume       = {12},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: